Clinic Conversation of the Week: Ponsegromab for Cancer Cachexia

8 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Read the full article on our website here: https://oncdata.com/ponsegromab-clinic-conversation-of-the-week

Explore groundbreaking insights into managing cancer cachexia with Dr. Waqas Haque, Medical Oncology Fellow at the University of Chicago, as he reviews findings from the phase 2 trial of ponsegromab, published in the New England Journal of Medicine. This innovative monoclonal antibody targets GDF15 to address appetite loss, weight decline, and muscle wasting in patients with advanced cancers.

- Learn how ponsegromab improved weight gain, muscle preservation, and physical activity with minimal side effects.
- Understand the role of GDF15 in appetite suppression and how ponsegromab blocks this pathway to improve nutritional status.
- Discover the potential for ponsegromab to enhance chemotherapy tolerance and overall quality of life in patients with lung, pancreatic, and colorectal cancers.

Dr. Haque highlights future directions, including comparisons with existing therapies and its potential application beyond oncology to conditions like heart failure and HIV-related cachexia.

#CancerCachexia #Ponsegromab #CancerTreatment #OncologyResearch #CancerCare #WeightLossTreatment #CancerSupport #Immunotherapy #GDF15Inhibitor #NEJM
Category
Oncology
Be the first to comment

Up Next